Rezolute (RZLT) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Offering details and pricing
Registration statement covers resale of up to 4,500,000 shares of common stock by certain selling stockholders, including shares issued under a securities purchase agreement and shares issuable upon exercise of pre-funded warrants.
Shares include 1,500,000 issued under a June 25, 2024 purchase agreement, 610,404 issued upon partial warrant exercise, and 2,389,596 issuable upon future warrant exercise.
Shares are validly issued, fully paid, and non-assessable; future warrant shares will be validly issued upon exercise and payment.
Use of proceeds and capital allocation
Registration is for resale by selling stockholders; proceeds from sales by these stockholders will not go to the company.
Risk factors and disclosures
Directors and officers are indemnified to the fullest extent permitted by Nevada law, with limitations for intentional misconduct, fraud, or knowing violations of law.
Indemnification agreements are in place for directors and executive officers, and an insurance policy covers certain liabilities.
SEC has advised that indemnification for Securities Act liabilities may be unenforceable as against public policy.
Latest events from Rezolute
- Net loss widened to $22.8M; cash and investments at $132.9M, with key trials ongoing.RZLT
Q2 202612 Feb 2026 - Antibody therapy for hyperinsulinism shows strong efficacy and targets rare disease markets.RZLT
Guggenheim Securities Inaugural Healthcare Innovation Conference14 Jan 2026 - All annual meeting proposals, including share and incentive plan increases, were approved.RZLT
AGM 202411 Jan 2026 - Ersodetug offers a novel solution for severe hypoglycemia in rare HI, targeting a $1B+ market.RZLT
Corporate Presentation9 Jan 2026 - Phase III data for a universal hyperinsulinism therapy expected in December, with BLA filing mid-2026.RZLT
Morgan Stanley 23rd Annual Global Healthcare Conference31 Dec 2025 - Late-stage metabolic disease therapies advance, $6M raised, 4.5M shares registered for resale.RZLT
Registration Filing16 Dec 2025 - Resale registration for 1.3M shares from a $4.2M private placement; lead drug in Phase 3 for rare HI.RZLT
Registration Filing16 Dec 2025 - Phase III Sunrise/sunRIZE study failed to show significant efficacy over placebo.RZLT
Study Result12 Dec 2025 - Late-stage antibody therapy targets severe hypoglycemia in rare HI, with $1B+ market potential.RZLT
Corporate Presentation11 Dec 2025